GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of genuine question about hazard ratio that I am slightly embarrassed to ask — 41 comments in the full submission. View in context.
904
c/trialwatch·submitted 6 months ago by u/tove_ogunleye

genuine question about hazard ratio that I am slightly embarrassed to ask

Readoutbranch of 7 comments

FLOW. That is the whole post, but I will justify it. Everything else people worry about in c/coa is downstream of it. Titration speed, early fullness, the endless dose arguments — most of it resolves if you sort FLOW out first, and almost nobody does. I say this having got it wrong for 10 months. My A1c was the thing…

Read the full submission and all 41 comments →

This branch

7 comments, started 6 months ago
u/nils_tulloch33 points·6 months ago

This is correct. Discontinuation arms show the regain reality.

replysharereportpermalink
u/hub_opssite staff7 points·6 months ago·edited

SELECT reported a hazard ratio hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/tove_ogunleyeOP4 points·6 months ago

SELECT reported a SELECT hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/tove_ogunleyeOP3 points·6 months ago

SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.

replysharereportpermalink
u/nordic_pricing3 points·6 months ago·edited

number-needed-to-treat is the house dialect

replysharereportpermalink
u/valeria_karlsen2 points·6 months ago

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink
u/milos_vanhecke1 point·6 months ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →